KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Gains from Investment Securities (2017 - 2026)

Pacira BioSciences has reported Gains from Investment Securities over the past 16 years, most recently at $4.4 million for Q1 2026.

  • For Q1 2026, Gains from Investment Securities rose 261.3% year-over-year to $4.4 million; the TTM value through Mar 2026 reached $4.7 million, up 202.77%, while the annual FY2025 figure was $5.6 million, 2280.08% up from the prior year.
  • Gains from Investment Securities for Q1 2026 was $4.4 million at Pacira BioSciences, up from $143000.0 in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $12.5 million in Q2 2022 and troughed at -$18.3 million in Q2 2023.
  • A 5-year average of $567294.1 and a median of $201000.0 in 2023 define the central range for Gains from Investment Securities.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 8909.35% in 2022 and later tumbled 1993.53% in 2024.
  • Year by year, Gains from Investment Securities stood at $9.6 million in 2022, then plummeted by 37.82% to $6.0 million in 2023, then tumbled by 102.97% to -$178000.0 in 2024, then skyrocketed by 180.34% to $143000.0 in 2025, then soared by 2945.45% to $4.4 million in 2026.
  • Business Quant data shows Gains from Investment Securities for PCRX at $4.4 million in Q1 2026, $143000.0 in Q4 2025, and $600000.0 in Q3 2025.